USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: IDEC PHARMACEUTICALS CORPORATION
City: SAN DIEGO
State: CA
Zip+4: 92121
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (858) 431-8813

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,025,893.00 17
SBIR Phase II $2,898,350.00 5
STTR Phase I $100,000.00 1

Award List:

MONOCLONAL ANTIBODY ANTI-IDIOTYPE TUMOR VACCINES

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E. Sobol , Principal Investigator
Award Amount: $49,996.00

MONOCLONAL ANTIBODY ANTI-IDIOTYPE TUMOR VACCINES

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: Robert E. Sobol , Principal Investigator
Award Amount: $455,000.00
Abstract:
The objective of this application is to develop monoclonal antibody (moab) anti-idiotype (anti-id) tumor vaccines for the treatment and prevention of cancer. the specific aims of the phase i proposal are to define the general principles for maximizing the in vivo efficacy of moab anti-id tumor… More

DIAGNOSTIC AND THERAPEUTIC APPLICATION OF ANTI-IDIOTYPES TO AIDS RELATED AUTOANTIBODIES

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Several recent studies have demonstrated a correlation between the development of autoantibodies to helper t cells and disease progression in human immunodeficiency virus (hiv) infections. the results of these studies have also indicated that these autoantibodies may contribute to the pathogenesis… More

MONOCLONAL ANTIBODIES TO COMMON TUMOR IDIOTOPES FOR TH THERAPY OF B-CELL NEOPLASMS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

MONOCLONAL ANTIBODIES TO COMMON TUMOR IDIOTOPES FOR TH THERAPY OF B-CELL NEOPLASMS

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $463,601.00
Abstract:
The main objective of this proposal is to develop efficacious immunotherapy for human b cell neoplasms employing anti-idiotype (anti-id) monoclonal antibodies (moabs). the specific aims of this phase i proposal are to develop anti-id moabs to lymphoma and chronic lymphocytic leukemia (cll)… More

DEVELOPMENT OF IMMUNOREGULATORY PEPTIDES FOR AIDS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas Kieber-emmons
Award Amount: $50,000.00
Abstract:
The need to develop effective immunoregulatory or antiviral reagents that will control hiv infection is paramount. in studies of the cd4 attachment site on the hiv envelope, a synthetic peptide that may be a strong candidate therapeutic agent has been identified. the peptide, termed a25d, represents… More

HU/SCID MOUSE MODEL: PREDICTING IMMUNOTHERAPY RESPONSES

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Heinz Kohler
Award Amount: $50,000.00
Abstract:
Active immunotherapy using anti-idiotypic antibodies that mimic tumor-associated antigens has been shown to be effective in animals and human patients. this research is aimed at optimizing the clinical response of malignant melanoma patients to anti-idiotype immunotherapy currently under… More

ANTI-CD4 ANTIBODY AS A THERAPEUTIC AND PREVENTIVE HIV VACCINE

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chang-yuil Kang
Award Amount: $50,000.00
Abstract:
Attempts to make a practical hiv vaccine have so far been unsuccessful. this research will use an anti-hiv receptor (cd4) antibody as an hiv vaccine to circumvent the current problems of hiv vaccine trials. the approach is based upon the assumption that certain anti-cd4 antibodies can structurally… More

CLONING HUMAN ANTI-GP120 B CELLS FOR AIDS THERAPY

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kohler, Heinz , Principal Investigator
Award Amount: $50,000.00
Abstract:
Hiv infection is characterized by a long asymptomatic state during which the immune state of the infected individual is not clinically impaired. during this time, neutralizing antibodies may play an important role in controlling virus replication and thereby maintaining the disease-free state. the… More

ANTI-T CELL RECEPTOR ANTIBODIES FOR CANCER IMMUNOTHERAPY

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raychaudhuri, Syamal , Principal Investigator
Award Amount: $50,000.00
Abstract:
The long-term objective of this program is to develop novel cancer immunotherapies based upon the ability of anti-t cell receptor (tcr) monoclonal antibodies (moabs) to stimulate immune responses. specifically, we plan to generate anti-clonotypic and anti-tcr moabs to t cell clones cytotoxic for… More

MOLECULAR CLONING AND EXPRESSION OF HUMAN ANTI-GP12

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Newman, Roland A , Principal Investigator
Award Amount: $50,000.00
Abstract:
Antibodies can be found in the sera of hiv seropositivparticular, antibodies are present which are reactive against various epitopes of the hiv envelope protein gp120. many of these are strain specific and react with hypervariable domains, while others, present at lower levels, are directed against… More

IDENTIFICATION OF PATHOGENIC AUTOANTIBODIES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Morrow, William J , Principal Investigator
Award Amount: $50,000.00
Abstract:
Sle is an autoimmune disease of unknown etiology which afflicts, primarily, women of child-bearing age. production of autoantibodies, particularly those specific for dna and other polynucleotides are central to the pathogenesis of the disease. the overall objective is to regulate autoantibody… More

THE ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kang, Chang-yuil , Principal Investigator
Award Amount: $50,000.00

THE ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kang, Chang-yuil , Principal Investigator
Award Amount: $500,000.00
Abstract:
Attempts to make a practical hiv vaccine have been unsuccessful to date. we will use anti-idiotype antibody (anti-id) as an hiv vaccine to elicit high titers of group-specific neutralizing antibodies. the principle of this approach is based on idiotype matching, which utilizes anti-ids as surrogates… More

CLASS I-RESTRICTED CTL INDUCTION BY SOLUBLE ANTIGENS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Syamal Raychaudhuri
Award Amount: $50,000.00
Abstract:
It is now well documented that cytotoxic t cell (ctl) responses play a crucial role in the control of viral infection in vivo. while a desirable characteristic of a vaccine or immunotherapeutic reagent is that in addition to antibody, it induces a ctl response, attempts to achieve this goal have… More

Human Monoclonal Antibody to Respiratory Syncytial Virus

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter Brams
Award Amount: $44,897.00

Monoclonal Antibodies From SCID-HU Mice

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter Brams
Award Amount: $81,000.00
Abstract:
We intend to generate human monoclonal antibodies to RSV F protein (F-prot) and prostatespecific antigen (PSA). Immunotherapy in a rat RSV model with monoclonal anti-F-prot antibodies hasworked, and murine anti-PSA antibodies are currently being used in an experimental clinical protocol fortreatment… More

CTL Induction by Soluble HPV 16 E7 Antigen

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amelia Black
Award Amount: $100,000.00
Abstract:
Infection with human papillovamirus (HPV) type l6 is strongly associated with the development of ceother ano-genital carcinomas. In more than 90 percent of cervical carcinomas HPV DNA can be detectedcarcinoma biopsies, the most consistently retained and expressed HPV genes are two early viral… More

Human Monoclonal Antibody to Respiratory Syncytial Virus

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Peter Brams
Award Amount: $750,000.00
Abstract:
Passive immunotherapy has been shown to be an effective method for controlling RSV infection. The virus envelope fusion (F protein) represents an ideal target for passive immunotherapy because antibodies to this protein typically bind to and neutralize both of the two clinical subgroups of this… More

HUMANIZATION OF A MURINE ANTIGP39 ANTIBODY

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

HUMANIZATION OF A MURINE ANTIGP39 ANTIBODY

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $729,749.00

ANTICD154 THERAPY & ALLOGENEIC BONE MARROW TRANSPLANTS

Award Year / Program / Phase: 1998 / STTR / Phase I
Agency: HHS
Research Institution: Dartmouth Medical School
Principal Investigator: Noelle
Award Amount: $100,000.00
RI Contact: N/A

THERAPEUTIC ANTICD23 ANTIBODY DIMERS FOR CLL

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kandasamy Hariharan
Award Amount: $100,000.00
Abstract:
Not Available Both energy storage and management are critical aspects of the development of practival MEMS sensors incorporating microbatteries. US Nanocorp has developed a patented fuzzy logic-based methodology to determine state-of-charge (SOC) in a wide variety of battery chemistries. … More